Marshall Wace LLP Sells 17,687,791 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Marshall Wace LLP trimmed its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 93.2% during the 2nd quarter, Holdings Channel reports. The fund owned 1,283,942 shares of the company’s stock after selling 17,687,791 shares during the period. Marshall Wace LLP’s holdings in Perspective Therapeutics were worth $12,801,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. ZWJ Investment Counsel Inc. purchased a new stake in shares of Perspective Therapeutics in the 1st quarter worth approximately $26,000. RIA Advisory Group LLC lifted its holdings in Perspective Therapeutics by 1,313.4% during the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock worth $127,000 after buying an additional 99,293 shares during the period. Bleakley Financial Group LLC bought a new stake in Perspective Therapeutics during the 1st quarter valued at $40,000. Vanguard Group Inc. increased its holdings in shares of Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after acquiring an additional 4,566,356 shares during the period. Finally, Affinity Asset Advisors LLC bought a new position in shares of Perspective Therapeutics in the 1st quarter worth $6,069,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Stock Up 2.5 %

CATX stock opened at $12.57 on Friday. Perspective Therapeutics, Inc. has a 52 week low of $2.20 and a 52 week high of $19.05. The stock has a 50 day moving average of $13.81.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.04. The company had revenue of $0.53 million for the quarter. As a group, equities research analysts forecast that Perspective Therapeutics, Inc. will post -0.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CATX shares. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Bank of America initiated coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They set a “buy” rating and a $24.00 price target for the company. Oppenheimer cut their price objective on shares of Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Royal Bank of Canada reduced their price objective on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a research note on Friday, August 16th. Finally, Truist Financial started coverage on shares of Perspective Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $21.00 target price for the company. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $20.00.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.